Gene · 55737
Papers2,077
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,077
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson's Disease Treatment. | Biomedicines | 2023 | 37626726 | PubTator, text mining | PubMed |
| Neurological Insights into Sleep Disorders in Parkinson's Disease. | Brain Sci | 2023 | 37626558 | PubTator, text mining | PubMed |
| Altered G-Protein Transduction Protein Gene Expression in the Testis of Infertile Patients with Nonobstructive Azoospermia. | DNA Cell Biol | 2023 | 37610843 | PubTator, text mining | PubMed |
| SNPs in cytochrome P450 genes decide on the fate of individuals with genetic predisposition to Parkinson's disease. | Front Pharmacol | 2023 | 37601072 | PubTator, text mining | PubMed |
| The mitophagy pathway and its implications in human diseases. | Signal Transduct Target Ther | 2023 | 37582956 | PubTator, text mining | PubMed |
| Impaired skeletal muscle health in Parkinsonian syndromes: clinical implications, mechanisms and potential treatments. | J Cachexia Sarcopenia Muscle | 2023 | 37574254 | PubTator, text mining | PubMed |
| Functional screening reveals Toxoplasma prenylated proteins required for endocytic trafficking and rhoptry protein sorting. | mBio | 2023 | 37548452 | PubTator, text mining | PubMed |
| VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease. | Mol Neurodegener | 2023 | 37542299 | PubTator, text mining | PubMed |
| Commanding the Commander: structure of a key protein machinery in endosomal trafficking. | Signal Transduct Target Ther | 2023 | 37542035 | PubTator, text mining | PubMed |
| CRB1 is required for recycling by RAB11A+ vesicles in human retinal organoids. | Stem Cell Reports | 2023 | 37541258 | PubTator, text mining | PubMed |
| Single-Cell Transcriptomics for Unlocking Personalized Cancer Immunotherapy: Toward Targeting the Origin of Tumor Development Immunogenicity. | Cancers (Basel) | 2023 | 37509276 | PubTator, text mining | PubMed |
| Mitochondrial Neurodegenerative Diseases: Three Mitochondrial Ribosomal Proteins as Intermediate Stage in the Pathway That Associates Damaged Genes with Alzheimer's and Parkinson's. | Biology (Basel) | 2023 | 37508402 | PubTator, text mining | PubMed |
| WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective. | Diseases | 2023 | 37489441 | PubTator, text mining | PubMed |
| Development of CRISPR Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson's disease. | Front Neurosci | 2023 | 37483347 | PubTator, text mining | PubMed |
| Should evidence of an autolysosomal de-acidification defect in Alzheimer and Parkinson diseases call for caution in prescribing chronic PPI and DMARD? | Autophagy | 2023 | 37482676 | PubTator, text mining | PubMed |
| Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review. | Int J Mol Sci | 2023 | 37446200 | PubTator, text mining | PubMed |
| Brain-Biomarker Changes in Body Fluids of Patients with Parkinson's Disease. | Int J Mol Sci | 2023 | 37446110 | PubTator, text mining | PubMed |
| Protein network analysis links the NSL complex to Parkinson's disease via mitochondrial and nuclear biology. | Mol Omics | 2023 | 37427757 | PubTator, text mining | PubMed |
| More than meets the eye in Parkinson's disease and other synucleinopathies: from proteinopathy to lipidopathy. | Acta Neuropathol | 2023 | 37421475 | PubTator, text mining | PubMed |
| Diversity of retromer-mediated vesicular trafficking pathways in plants. | Front Plant Sci | 2023 | 37409293 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55737/papers?page=10